Actively Recruiting
Prognostic Markers of Acute Heart Failure With Chronic Kidney Disease
Led by Cheng-Hsin General Hospital · Updated on 2024-08-23
155
Participants Needed
1
Research Sites
155 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Acute heart failure (AHF) is defined as new or worsening of symptoms and signs of heart failure and is the most frequent cause of unplanned hospital admission in elderly patients. N-terminal pro-brain natriuretic peptide (NT-pro-BNP) is one of the most developed prognostic markers for AHR patients and. NT-pro-BNP has limitations in terms of diagnostic or predictive accuracy in patients with chronic kidney disease (CKD). Plasma proteomics have the potential to examine underlying pathophysiological and prognostic roles, so we compared the plasma proteomic signature to predict outcomes of patients with or without CKD hospitalized for AHF.
CONDITIONS
Official Title
Prognostic Markers of Acute Heart Failure With Chronic Kidney Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Hospitalized for acute heart failure
You will not qualify if you...
- Initial serum NT-proBNP level below 300 ng/ml
- Pregnancy
- Amputated
- End-stage renal disease under regular dialysis
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Cheng Hsin General Hospital
Taipei, Baitou District, Taiwan, 112
Actively Recruiting
Research Team
S
Shang Feng Yang, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here